In this study, we evaluate a STAT6 3′ UTR-targeting, single-stranded DNA ASOs, with the objective to downregulate the expression of all NAB2-STAT6 fusion transcripts, in an effort to exert anti-tumor benefits for SFTs. This evidence concerns the gene NAB2 and neoplasm.